Press coverage about Enzymotec (NASDAQ:ENZY) has been trending somewhat positive on Sunday, according to Accern Sentiment Analysis. Accern identifies positive and negative press coverage by monitoring more than twenty million blog and news sources. Accern ranks coverage of public companies on a scale of negative one to one, with scores closest to one being the most favorable. Enzymotec earned a coverage optimism score of 0.11 on Accern’s scale. Accern also gave media coverage about the biotechnology company an impact score of 45.8079035947563 out of 100, meaning that recent press coverage is somewhat unlikely to have an impact on the company’s share price in the immediate future.
Shares of NASDAQ:ENZY opened at $11.85 on Friday. Enzymotec has a 1 year low of $6.30 and a 1 year high of $12.35.
Separately, BidaskClub downgraded Enzymotec from a “hold” rating to a “sell” rating in a research note on Saturday, January 6th. One research analyst has rated the stock with a sell rating and four have given a hold rating to the company. Enzymotec currently has a consensus rating of “Hold” and a consensus target price of $11.75.
COPYRIGHT VIOLATION WARNING: This piece was reported by Dispatch Tribunal and is the property of of Dispatch Tribunal. If you are reading this piece on another domain, it was illegally copied and republished in violation of US and international copyright and trademark legislation. The correct version of this piece can be read at https://www.dispatchtribunal.com/2018/04/08/somewhat-favorable-press-coverage-somewhat-unlikely-to-impact-enzymotec-enzy-share-price.html.
Enzymotec Company Profile
Enzymotec Ltd. is a nutritional ingredients and medical foods company. The Company’s technologies, research expertise and clinical validation process enables it to develop solutions across a range of products. The Company operates in two segments: Nutrition segment and VAYA Pharma segment. Both of the Company’s segments offer a range of products that leverage its lipid-related offerings.
Receive News & Ratings for Enzymotec Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Enzymotec and related companies with MarketBeat.com's FREE daily email newsletter.